Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Gyre Therapeutics, Inc.NASDAQ: GYRE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$8.57M, compared with $5.17M a year earlier. Trailing-twelve-month EBITDA was $3.16M. Over 3 fiscal years it compounded at +17.2% a year.
Context
- EBITDA amounted to 14.5% of revenue in FY2025, down 2.3 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$27.11M (-259.9%) for the fiscal year ending Dec 2026, a slowdown from the -4.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.57M-1461.7% QoQ
- Last fiscal yearDec 2025
- $16.96M-4.8% YoY
- LTMMar 2026
- $3.16M-81.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -265.7% | -261.4% | +4.2 pp |
| 1 year | -4.8% | -259.9% | -255.1 pp |
| 3-year CAGR | +17.2% | +156.4% | +139.3 pp |
| 5-year CAGR | +34.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 16.96M USD
- Year-over-year change
- -4.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.96M | -4.8% |
| FY2024 | 2024-12-31 | 17.82M | -12.3% |
| FY2023 | 2023-12-31 | 20.33M | +92.8% |
| FY2022 | 2022-12-31 | 10.54M | +112.0% |
| FY2021 | 2021-12-31 | (87.64M) | — |
EBITDA vs competitors
How GYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -81.4% is the 3rd highest of 5, against a peer median of -118.4%.
- EBITDA amounts to 2.7% of revenue for GYRE, versus a peer median of 4567.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.16M USD | -81.4% | +17.2% | 2.7% | |
| LTM Mar 2026 | -$18.62M USD | +52.1% | — | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€45.89M EUR | -286.3% | — | — |
| LTM Mar 2026 | -$107.98M USD | +49.6% | — | — | |
| LTM Mar 2026 | -$342.25M USD | -325.9% | — | 4567.0% | |
| Peer median (excluding GYRE) | — | -118.4% | — | 4567.0% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.34M | 102.29M | 113.45M | 105.76M | 116.59M |
| Cost of Revenue | 7.67M | 4.79M | 4.64M | 3.88M | 5.42M |
| Gross Profit | (332K) | 97.5M | 108.81M | 101.87M | 111.17M |
| Gross Margin | -4.5% | 95.3% | 95.9% | 96.3% | 95.4% |
| Research & Development | 64.57M | 16.69M | 13.78M | 12.02M | 13.7M |
| Selling, General & Admin | 18.82M | 71.61M | 75.82M | 73.62M | 85.98M |
| Operating Expenses | 83.39M | 88.29M | 176.04M | 85.71M | 99.68M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.52M |
| EBITDA | (87.64M) | 10.54M | 20.33M | 17.82M | 16.96M |
| EBITDA Margin | -1194.4% | 10.3% | 17.9% | 16.8% | 14.5% |
| Operating Income | (83.73M) | 9.2M | (67.23M) | 16.16M | 11.49M |
| Operating Margin | -1141.0% | 9.0% | -59.3% | 15.3% | 9.9% |
| Interest Income | 39K | 726K | 1.04M | 1.55M | 1.75M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.21M) | 209K | (9.74M) | 7.06M | 2.95M |
| Income Before Tax | (87.93M) | 9.41M | (76.97M) | 23.22M | 14.44M |
| Pre-Tax Margin | -1198.3% | 9.2% | -67.8% | 22.0% | 12.4% |
| Income Tax Expense | 0 | 5.1M | 8.52M | 5.32M | 4.56M |
| Net Income | (87.93M) | 2.3M | (92.93M) | 12.09M | 5.03M |
| Net Margin | -1198.3% | 2.3% | -81.9% | 11.4% | 4.3% |
| EPS (Basic) | (2.87) | 0.03 | (1.41) | 0.14 | 0.06 |
| EPS (Diluted) | (2.87) | 0.03 | (1.41) | 0.05 | 0.02 |
| Weighted Avg Shares | 30.64M | 76.74M | 65.83M | 85.09M | 89.34M |
| Weighted Avg Shares (Diluted) | 30.64M | 75.69M | 65.83M | 102.29M | 103.18M |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.